These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 23679231)

  • 1. Heart failure in patients treated with bisphosphonates.
    Grove EL; Abrahamsen B; Vestergaard P
    J Intern Med; 2013 Oct; 274(4):342-50. PubMed ID: 23679231
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Acute myocardial infarction and atherosclerosis of the coronary arteries in patients treated with drugs against osteoporosis: calcium in the vessels and not the bones?
    Vestergaard P
    Calcif Tissue Int; 2012 Jan; 90(1):22-9. PubMed ID: 22120197
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Alendronate and raloxifene use related to cardiovascular diseases: differentiation by different dosing regimens of alendronate.
    Lu PY; Hsieh CF; Tsai YW; Huang WF
    Clin Ther; 2011 Sep; 33(9):1173-9. PubMed ID: 21849210
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Risk of atrial fibrillation associated with use of bisphosphonates and other drugs against osteoporosis: a cohort study.
    Vestergaard P; Schwartz K; Pinholt EM; Rejnmark L; Mosekilde L
    Calcif Tissue Int; 2010 May; 86(5):335-42. PubMed ID: 20309678
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Atrial fibrillation in fracture patients treated with oral bisphosphonates.
    Abrahamsen B; Eiken P; Brixen K
    J Intern Med; 2009 May; 265(5):581-92. PubMed ID: 19141097
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Oral bisphosphonate use increases the risk for inflammatory jaw disease: a cohort study.
    Vestergaard P; Schwartz K; Rejnmark L; Mosekilde L; Pinholt EM
    J Oral Maxillofac Surg; 2012 Apr; 70(4):821-9. PubMed ID: 21764202
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gastric and esophagus events before and during treatment of osteoporosis.
    Vestergaard P; Schwartz K; Pinholt EM; Rejnmark L; Mosekilde L
    Calcif Tissue Int; 2010 Feb; 86(2):110-5. PubMed ID: 19957165
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Proton pump inhibitor use and the antifracture efficacy of alendronate.
    Abrahamsen B; Eiken P; Eastell R
    Arch Intern Med; 2011 Jun; 171(11):998-1004. PubMed ID: 21321287
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Occurrence of gastrointestinal cancer in users of bisphosphonates and other antiresorptive drugs against osteoporosis.
    Vestergaard P
    Calcif Tissue Int; 2011 Dec; 89(6):434-41. PubMed ID: 22002678
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Determinants of persistence with bisphosphonates: a study in women with postmenopausal osteoporosis.
    Penning-van Beest FJ; Goettsch WG; Erkens JA; Herings RM
    Clin Ther; 2006 Feb; 28(2):236-42. PubMed ID: 16678644
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Stroke in relation to use of raloxifene and other drugs against osteoporosis.
    Vestergaard P; Schwartz K; Pinholt EM; Rejnmark L; Mosekilde L
    Osteoporos Int; 2011 Apr; 22(4):1037-45. PubMed ID: 20449570
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Osteoporosis treatment and atrial fibrillation: alendronate versus raloxifene.
    Huang WF; Tsai YW; Wen YW; Hsiao FY; Kuo KN; Tsai CR
    Menopause; 2010; 17(1):57-63. PubMed ID: 19680161
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Use of bisphosphonates and risk of breast cancer.
    Vestergaard P; Fischer L; Mele M; Mosekilde L; Christiansen P
    Calcif Tissue Int; 2011 Apr; 88(4):255-62. PubMed ID: 21253712
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Risk of femoral shaft and subtrochanteric fractures among users of bisphosphonates and raloxifene.
    Vestergaard P; Schwartz F; Rejnmark L; Mosekilde L
    Osteoporos Int; 2011 Mar; 22(3):993-1001. PubMed ID: 21165600
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Risk of newly diagnosed type 2 diabetes is reduced in users of alendronate.
    Vestergaard P
    Calcif Tissue Int; 2011 Oct; 89(4):265-70. PubMed ID: 21710315
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Use of bisphosphonates and raloxifene and risk of deep venous thromboembolism and pulmonary embolism.
    Vestergaard P; Schwartz K; Pinholt EM; Rejnmark L; Mosekilde L
    Osteoporos Int; 2010 Sep; 21(9):1591-7. PubMed ID: 19859641
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Incidence and risk of venous thromboembolism among Taiwan osteoporotic fracture population under osteoporosis pharmacological treatments.
    Lin TC; Lee CH; Yang CY; Yang YH; Lin SJ
    J Clin Endocrinol Metab; 2014 May; 99(5):1599-607. PubMed ID: 24606074
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Esophageal and gastric cancer incidence and mortality in alendronate users.
    Abrahamsen B; Pazianas M; Eiken P; Russell RG; Eastell R
    J Bone Miner Res; 2012 Mar; 27(3):679-86. PubMed ID: 22113985
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Use of oral bisphosphonates and the risk of aseptic osteonecrosis: a nested case-control study.
    Etminan M; Aminzadeh K; Matthew IR; Brophy JM
    J Rheumatol; 2008 Apr; 35(4):691-5. PubMed ID: 18203310
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differences in adherence to osteoporosis regimens: a 2-year analysis of a population treated under specific guidelines.
    Cheng TT; Yu SF; Hsu CY; Chen SH; Su BY; Yang TS
    Clin Ther; 2013 Jul; 35(7):1005-15. PubMed ID: 23831360
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.